Mikrobiomik launches a Capital Cell funding campaign to support its next clinical trial

Basque biotech company Mikrobiomik has launched a funding campaign on the Capital Cell investment platform to complete a financing round  aimed at advancing its next strategic milestones: the clinical expansion and market entry of its lead candidate MBK-01.

Proceeds will support the development of new clinical indications for MBK-01 —an oral microbiota-based biological therapy made from complete, purified intestinal microbiota— with ongoing clinical trials in recurrent diverticulitis (Phase II, DIREBIOT) and decompensated liver cirrhosis (Phase III, LiverGut). MBK-01 has already demonstrated efficacy and safety in a Phase III trial in Clostridioides difficile infection (CDI) and has been administered to over 100 patients in Spanish public hospitals under a compassionate use program authorized by the AEMPS.
The goal of the campaign is to complete a financing round that will fund the next major milestone for Mikrobiomik: a Phase II clinical trial for its flagship product MBK-01. This live biotherapeutic aims to treat recurrent Clostridioides difficile infections.

Interest among private investors has been strong from the outset, with over 150 individuals already taking part. The company has opened a €500,000 tranche for private investors, which is filling up at a fast pace.

Mikrobiomik is among the few European companies developing microbiota-based therapies under the full spectrum microbiota framework, with ambitions of becoming a global leader in this emerging therapeutic space.